Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United…

Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness; it encompasses multiple forms of chronic arthritis in children…

Prior to 2016, the therapeutic landscape for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) had only benefited from the introduction of one novel treatment, Erbitux,…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…

MARKET OUTLOOK There are multiple well-established therapies available to treat Crohn’s disease (CD). In particular, the mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen/…

The hepatitis B virus (HBV) therapy market is primarily defined by patients chronically infected with HBV who require lifelong treatment with a daily nucleoside analogue. Although the majority of…

As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) was launched nearly two decades ago and transformed the treatment of this disease by…